Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial Testing the Safety of a Humanized Monoclonal Antibody Anti-CD20 in Patients With Heart Failure With Reduced Ejection Fraction

NCT03332888 is registered in ClinicalTrials.gov with Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud as lead sponsor.

NCT NCT03332888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03332888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial Testing the Safety of a Humanized Monoclonal Antibody Anti-CD20 in Patients With Heart Failure With Reduced Ejection Fraction
Lead sponsor
Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2021
Completion date
July 15, 2021
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction